(GRAL) GRAIL - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 2.912m USD | Total Return: 62.9% in 12m
Avg Turnover: 33.9M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Share dilution 18.5% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Fakeout
Tailwinds
Idiosyncratic Leader
GRAIL, Inc. (GRAL) is a commercial-stage healthcare company specializing in multi-cancer early detection. The company offers Galleri, a screening test for asymptomatic individuals over 50, addressing a significant market need for early cancer detection, which can improve treatment outcomes.
GRAIL also provides diagnostic aid for cancer tests and development services for clinical studies and research. Its business model includes a precision oncology portfolio featuring a methylation-based platform for applications like disease prognostication and minimal residual disease detection, a rapidly evolving area within oncology.
To further understand GRAILs market position and financial health, consider exploring its detailed analytics on ValueRay.
- Galleri test adoption drives revenue growth
- Regulatory approval delays impact international expansion
- Clinical study outcomes influence investor confidence
- Reimbursement policies affect test accessibility and sales
- Research and development costs weigh on profitability
| Net Income: -395.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 6.03 > 1.0 |
| NWC/Revenue: 514.1% < 20% (prev 499.3%; Δ 14.79% < -1%) |
| CFO/TA -0.10 > 3% & CFO -291.0m > Net Income -395.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.6m) vs 12m ago 18.46% < -2% |
| Gross Margin: -14.80% > 18% (prev -0.58%; Δ -1.42k% > 0.5%) |
| Asset Turnover: 5.53% > 50% (prev 4.59%; Δ 0.94% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.29 (Total Current Assets 877.3m - Total Current Liabilities 74.7m) / Total Assets 2.80b |
| B: -3.68 (Retained Earnings -10.3b / Total Assets 2.80b) |
| C: -0.18 (EBIT TTM -516.3m / Avg Total Assets 2.83b) |
| D: -34.03 (Book Value of Equity -10.3b / Total Liabilities 302.8m) |
| Altman-Z'' = -47.06 = D |
| DSRI: 0.88 (Receivables 20.3m/19.4m, Revenue 156.1m/130.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.93 (AQ_t 0.65 / AQ_t-1 0.70) |
| SGI: 1.19 (Revenue 156.1m / 130.7m) |
| TATA: -0.04 (NI -395.3m - CFO -291.0m) / TA 2.80b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 68.96 with a total of 935,090 shares traded.
Over the past week, the price has changed by +13.59%,
over one month by +25.34%,
over three months by +18.69% and
over the past year by +62.87%.
GRAIL has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold GRAL.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 66.9 | -3% |
P/S = 18.6544
P/B = 1.1646
Revenue TTM = 156.1m USD
EBIT TTM = -516.3m USD
EBITDA TTM = -360.5m USD
Long Term Debt = 41.1m USD (estimated: total debt 51.0m - short term 9.94m)
Short Term Debt = 9.94m USD (from shortTermDebt, last quarter)
Debt = 51.0m USD (from shortLongTermDebtTotal, last quarter) (leases 51.0m already included)
Net Debt = -772.1m USD (calculated: Debt 51.0m - CCE 823.1m)
Enterprise Value = 2.14b USD (2.91b + Debt 51.0m - CCE 823.1m)
Interest Coverage Ratio = unknown (Ebit TTM -516.3m / Interest Expense TTM 0.0)
EV/FCF = -7.34x (Enterprise Value 2.14b / FCF TTM -291.4m)
FCF Yield = -13.62% (FCF TTM -291.4m / Enterprise Value 2.14b)
FCF Margin = -186.7% (FCF TTM -291.4m / Revenue TTM 156.1m)
Net Margin = -253.2% (Net Income TTM -395.3m / Revenue TTM 156.1m)
Gross Margin = -14.80% ((Revenue TTM 156.1m - Cost of Revenue TTM 179.2m) / Revenue TTM)
Gross Margin QoQ = 47.91% (prev -25.54%)
Tobins Q-Ratio = 0.76 (Enterprise Value 2.14b / Total Assets 2.80b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 51.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -407.9m (EBIT -516.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.74 (Total Current Assets 877.3m / Total Current Liabilities 74.7m)
Debt / Equity = 0.02 (Debt 51.0m / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = 2.14 (negative EBITDA) (Net Debt -772.1m / EBITDA -360.5m)
Debt / FCF = 2.65 (negative FCF - burning cash) (Net Debt -772.1m / FCF TTM -291.4m)
Total Stockholder Equity = 2.41b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.99% (Net Income -395.3m / Total Assets 2.80b)
RoE = -3.11% (Net Income TTM -395.3m / Total Stockholder Equity 12.7b)
RoCE = -4.05% (EBIT -516.3m / Capital Employed (Equity 12.7b + L.T.Debt 41.1m))
RoIC = -15.93% (negative operating profit) (NOPAT -407.9m / Invested Capital 2.56b)
WACC = 11.11% (E(2.91b)/V(2.96b) * Re(11.30%) + D(51.0m)/V(2.96b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 12.70%
[DCF] Fair Price = unknown (Cash Flow -291.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.54 | # QB: 0
Revenue Correlation: 98.46 | Revenue CAGR: 25.73% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.21 | Chg30d=-3.50% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-2.21 | Chg30d=+0.82% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=-8.47 | Chg30d=+6.27% | Revisions=-20% | GrowthEPS=+27.6% | GrowthRev=+22.4%
EPS next Year (2027-12-31): EPS=-9.18 | Chg30d=-1.41% | Revisions=-20% | GrowthEPS=-8.3% | GrowthRev=+24.5%
[Analyst] Revisions Ratio: -20%